Nuvation Bio Q3 net loss $19.6M ($0.09/shr), cash $619.3M; DDC IND on track

Nuvation Bio Inc.

2023-Q3 EPS reported -$0.28

Net loss narrowed to $19.6M from $27.2M YoY; loss per share $0.09 vs $0.12.
Cash, equivalents and marketable securities totaled $619.3M as of Sept 30, 2023.
R&D expenses fell to $18.6M from $21.3M, driven by NUV-422 termination and headcount reduction.
Phase 1 monotherapy and Phase 1b combo studies of NUV-868 (BETi) ongoing in advanced solid tumors.
IND submission for first Drug-Drug Conjugate candidate expected by year-end 2023.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Nuvation Bio Inc. reported the third quarter ended September 30, 2023 results: net income net loss of $19.6 million, or $(0.09) per share, EPS $(0.09) per share.

Period: the third quarter ended September 30, 2023
Net income: net loss of $19.6 million, or $(0.09) per share
EPS: $(0.09) per share
Result: reported results

Exact text from the filing

Nuvation Bio Inc. issued a press release announcing its financial results for the quarter ended September 30, 2023

View on SEC.gov

3 earnings releases filed in the last 30 days. Browse all earnings releases →

Nuvation Bio Inc. filing history →

Source: SEC EDGAR

accession 0001193125-23-269399

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.